Table 1. Patient characteristics.

Subject	Primary tumor	Liver intervention and chemotherapy regimens	TIPS indication	MELD Na	Clinical outcome	Follow up (months) and survival
1	Colorectal	Hepatic lobectomy; cyberknife; FOLFOX, avastin, FOLFIRI, modified FOLFOX; partial PVT	AVB	18	No further bleeding	9.8, death
2	Colorectal	Wedge resection; RFA, TACE; FOLFOX, avastin, FOLFIRINOX, 5-FU, capecitabine, FOLFIRI/cetuximab	AVB	11	No further bleeding	2.62, death
3	Colorectal	TARE, FOLFOX, Avastin, 5FU, LV, FOLFIRI/cetuximab, irinotecan, capecitabine	Ascites	14	No further LVP; TIPS occlusion requiring revision ×2	38.6, death
4	Colorectal	FOLFOX, 5FU, leucovorin	Ascites	21	No further LVP	0.3, death
5	Colorectal	FOLFOX, avastin; FU/LV	Ascites	13	TIPS occlusion requiring revision; multiple LVPs required	2.4, death
6	NET	TACE; PRRT	Ascites	11	No further LVP	17.5, death
7	NET	Wedge resection; splenic vein to portosystemic shunt	AVB	16	Technically unsuccessful; pancreatectomy/splenectomy and Sugiura	2.3, death
8	NET	Aspira catheter	Ascites	20	Aspira catheter removal	1.2, death
9	Epithelioid hemangioendothelioma	Avastin; OLT	Ascites	17	TIPS occlusion requiring revision; 1 post TIPS LVP required	59.5, alive, asymptomatic

AVB, acute variceal bleeding; FOLFOX, 5-fluorouracil, oxaliplatin, leucovorin, FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; LVP, large volume paracentesis; NET, neuroendocrine tumor; OLT, orthotopic liver transplant; PRRT, peptide receptor radionuclide therapy; PVT, portal vein thrombosis; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TARE, transarterial radioembolization; TIPS, transjugular intrahepatic portosystemic shunt.